in-PharmaTechnologist presents its latest round up movements in the pharma sector, including CytRx bolstering its manufacturing expertise and KV preparing its management as it strives to resume distribution.
KV Pharmaceutical has begun rehiring employees to produce verification batches of certain products prior to resuming commercial manufacture, which appears to be on schedule after the FDA accepted the work plan.
KV Pharmaceutical found deficiencies and instances of noncompliance during its internal investigation, which was launched in response to issues with the FDA and allegations of management misconduct.
